Product
GR1802
Aliases
GR1802 injection, Xeligekimab
5 clinical trials
3 indications
Indication
Allergic RhinitisIndication
Atopic DermatitisIndication
Chronic RhinosinusitisClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR.Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 Injection in Patients With Moderate to Severe Atopic DermatitisStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety of GR1802 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Status: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
An Open-label, Single-arm, Multicenter, Extension Study to Evaluate the Long-term Safety and Efficacy of GR1802 Injection in Patients With Chronic Rhinosinusitis With Nasal PolypsStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
The Efficacy and Safety of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment: A Randomized, Double-Blind, Placebo-controlled Investigator Initiated Trial.Status: Recruiting, Estimated PCD: 2023-11-01